AstraZeneca, Array BioPharma cancer deal results in lawsuit

Feb 02, 2018


Colorado-based Array BioPharma has sued AstraZeneca, accusing the drugmaker of refusing to pay royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck.

According to the complaint, Array is seeking at least $192 million from AstraZeneca following the alleged breach of a 2003 licensing agreement related to  Array's drug, selumetinib. Array said the agreement allowed AstraZeneca to use selumetinib in research to fight cancer, and provided for a 12-percent royalty on sums that AstraZeneca might receive from sub-licensees, such as Merck.

In the July 2017 collaboration, AstraZeneca and Merck agreed to independently develop and commercialize Merck’s Lynparza and AstraZeneca's potential medicine selumetinib in combinations with companies’ respective PD-L1/PD-1 immuno-oncology meds, Imfinzi and Keytruda.

Now, Array wants its royalties on AstraZeneca's expected $1.6 billion upfront payment from Merck. The $192 million sought represents 12 percent of that payment.

Read the Reuters coverage


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments